01 January 2005
Raloxifene does not prevent fi brinogen oxidation in vitro
Margit Blasbichler, Arsineh Arakil-Aghajanian, Helmut SinzingerMed Sci Monit 2005; 11(1): PI1-4 :: ID: 13882
Abstract
Background: Modifi cation of proteins may play a central role in a great variety of pathophysiological processes.It has already been ascertained that raloxifene (LY 139481), a selective estrogen receptor modulator (SERM), is an effective inhibitor of LDL oxidation. herefore, we examined potential anti-oxidant activity related to the oxidation of the glycoprotein fi brinogen.Materials/Methods: In this study we investigated whether raloxifene is able to inhibit in vitro iron-mediated oxidation of fi brinogen. We tested three different concentrations of raloxifene (5, 10, and 125 µM) corresponding to the usual dosage in postmenopausal women of between 10 and 300 mg/day, choosing two incubation periods (60 and 120 min).Results: Our results in the examined dose-range provide no evidence that raloxifene is able to prevent ironinduced fi brinogen oxidation in vitro. Considering the chemical structure of the glycoprotein fi - brinogen, it is likely that raloxifene is unable to attack a particle without lipophilic properties, although the site of its action on LDL is still unknown.Conclusions: Our data suggest that raloxifene, in contrast to its effect on LDL, lacks the capability to inhibit the oxidation of fi brinogen. The biological relevance of this fi nding still needs to be assessed in vivo.
Keywords: Fibrinogen - chemistry, Raloxifene - chemistry, Antioxidants - chemistry, Fibrinogen - chemistry, Iron - chemistry, Oxidation-Reduction, Raloxifene - chemistry
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952